Poor
Mostly Aligned
Patient Risk:
Medium
Summary
The AI response is largely not a drug-label-aligned dosing/safety summary for STROMECTOL and does not ground most statements in the provided FDA-approved label excerpts. While several general safety red-flag statements are not directly contradicted, they are mostly unsupported or outside the scope of the provided prescribing information, resulting in low overall alignment.
Category Scores
Accurate Statements
“The correct dosing of ivermectin depends on body weight and the condition being treated.”
Label excerpt (Dosage and Administration) states recommended single-dose regimens are calculated to provide ~200 mcg/kg for strongyloidiasis and ~150 mcg/kg for onchocerciasis, i.e., dose is weight-based and depends on condition.
“Using the wrong dose or wrong indication of ivermectin can lead to serious side effects.”
Label excerpt includes warnings about neurotoxicity with ivermectin use and notes adverse reactions; however, the label excerpt does not explicitly tie seriousness to “wrong dose or wrong indication.” Partial support only via general existence of serious adverse reactions.
Unsupported Statements
“Onlypharmacies” is not a recognizable, official pharmacy chain or regulatory term on its own.
Not supported by the provided STROMECTOL FDA label excerpts (not a drug label claim).
“It is hard to say where “onlypharmacies” ships from.”
Not supported by the provided prescribing information.
“It is hard to say whether “onlypharmacies” is licensed.”
Not supported by the provided prescribing information.
“It is hard to say whether the product is genuine.”
Not supported by the provided prescribing information.
“Ivermectin 12 mg tablets are prescription medicines in many places.”
Not addressed in the provided STROMECTOL label excerpts (regulatory status by location not included).
“Buying ivermectin from an unverified source is a major safety risk.”
No such statement is included in the provided STROMECTOL label excerpts.
“In many countries, ivermectin is prescription-only for most indications.”
Not addressed in the provided STROMECTOL label excerpts.
“If a site listing for generic ivermectin 12 mg does not clearly provide sufficient verification details (drug name, dose, dosage form, manufacturer name and batch/lot, prescription handling rules), it should be treated as a red flag.”
No corresponding guidance exists in the provided STROMECTOL label excerpts.
Contradictions
Important Omissions
FDA-label-aligned dosing specifics for STROMECTOL include that patients should take tablets on an empty stomach with water, that follow-up stool examinations should verify eradication for strongyloidiasis, and that additional doses are generally not necessary (strongyloidiasis), plus retreatment interval considerations (onchocerciasis).
Importance:
Moderate
Key STROMECTOL contraindication (hypersensitivity to any component) was not mentioned.
Importance:
Moderate
Label-specific warnings/precautions related to neurotoxicity and Loa loa assessment in onchocerciasis contexts were not mentioned with any label-level specificity.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response contains several general safety assertions about unverified sources and prescription status that are not grounded in the provided STROMECTOL FDA label excerpts. It does not provide core label safety/administration details, though it does include at least one partially label-aligned statement about weight-based dosing by condition.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most statements are not prescribing-information-aligned for STROMECTOL and are unsupported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to the provided STROMECTOL label sections. Include label-specific dosing/administration (empty stomach with water), follow-up/testing for strongyloidiasis (stool examinations), contraindication (hypersensitivity), and label warnings (neurotoxicity; Loa loa assessment/monitoring for onchocerciasis). Remove or clearly separate non-label assertions about retailers, authenticity, and country-specific prescription status unless supported by FDA labeling.